China · Delayed Price · Currency is CNY Novogene Statistics
Total Valuation
Novogene has a market cap or net worth of CNY 7.87 billion. The enterprise value is 6.24 billion.
| Market Cap | 7.87B |
| Enterprise Value | 6.24B |
Important Dates
The last earnings date was Wednesday, August 26, 2026.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Novogene has 405.06 million shares outstanding. The number of shares has decreased by -3.60% in one year.
| Current Share Class | 405.06M |
| Shares Outstanding | 405.06M |
| Shares Change (YoY) | -3.60% |
| Shares Change (QoQ) | -12.46% |
| Owned by Insiders (%) | 53.05% |
| Owned by Institutions (%) | 8.15% |
| Float | 136.65M |
Valuation Ratios
The trailing PE ratio is 51.03 and the forward PE ratio is 37.75.
| PE Ratio | 51.03 |
| Forward PE | 37.75 |
| PS Ratio | 3.45 |
| PB Ratio | 2.91 |
| P/TBV Ratio | 2.97 |
| P/FCF Ratio | 35.92 |
| P/OCF Ratio | 22.17 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.11, with an EV/FCF ratio of 28.48.
| EV / Earnings | 41.26 |
| EV / Sales | 2.73 |
| EV / EBITDA | 23.11 |
| EV / EBIT | 44.78 |
| EV / FCF | 28.48 |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.57 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 0.42 |
| Interest Coverage | 59.26 |
Financial Efficiency
Return on equity (ROE) is 5.88% and return on invested capital (ROIC) is 11.40%.
| Return on Equity (ROE) | 5.88% |
| Return on Assets (ROA) | 2.32% |
| Return on Invested Capital (ROIC) | 11.40% |
| Return on Capital Employed (ROCE) | 5.02% |
| Weighted Average Cost of Capital (WACC) | 8.20% |
| Revenue Per Employee | 1.03M |
| Profits Per Employee | 67,957 |
| Employee Count | 2,227 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 5.00 |
Taxes
In the past 12 months, Novogene has paid 17.72 million in taxes.
| Income Tax | 17.72M |
| Effective Tax Rate | 10.21% |
Stock Price Statistics
The stock price has increased by +25.83% in the last 52 weeks. The beta is 0.73, so Novogene's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +25.83% |
| 50-Day Moving Average | 14.46 |
| 200-Day Moving Average | 14.27 |
| Relative Strength Index (RSI) | 74.71 |
| Average Volume (20 Days) | 10,379,903 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novogene had revenue of CNY 2.28 billion and earned 151.34 million in profits. Earnings per share was 0.38.
| Revenue | 2.28B |
| Gross Profit | 979.93M |
| Operating Income | 139.42M |
| Pretax Income | 173.61M |
| Net Income | 151.34M |
| EBITDA | 249.81M |
| EBIT | 139.42M |
| Earnings Per Share (EPS) | 0.38 |
Balance Sheet
The company has 1.75 billion in cash and 91.43 million in debt, with a net cash position of 1.66 billion or 4.09 per share.
| Cash & Cash Equivalents | 1.75B |
| Total Debt | 91.43M |
| Net Cash | 1.66B |
| Net Cash Per Share | 4.09 |
| Equity (Book Value) | 2.71B |
| Book Value Per Share | 6.62 |
| Working Capital | 1.75B |
Cash Flow
In the last 12 months, operating cash flow was 355.14 million and capital expenditures -135.91 million, giving a free cash flow of 219.23 million.
| Operating Cash Flow | 355.14M |
| Capital Expenditures | -135.91M |
| Depreciation & Amortization | 110.39M |
| Net Borrowing | -17.94M |
| Free Cash Flow | 219.23M |
| FCF Per Share | 0.54 |
Margins
Gross margin is 42.92%, with operating and profit margins of 6.11% and 6.63%.
| Gross Margin | 42.92% |
| Operating Margin | 6.11% |
| Pretax Margin | 7.60% |
| Profit Margin | 6.63% |
| EBITDA Margin | 10.94% |
| EBIT Margin | 6.11% |
| FCF Margin | 9.60% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.23%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.23% |
| Dividend Growth (YoY) | -10.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 12.04% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.60% |
| Shareholder Yield | 3.83% |
| Earnings Yield | 1.92% |
| FCF Yield | 2.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novogene is 17.25, which is -11.04% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | 17.25 |
| Price Target Difference | -11.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 11.16% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novogene has an Altman Z-Score of 4.71 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.71 |
| Piotroski F-Score | 4 |